Immunic, Inc.
IMUX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001280776
No open-market purchases or sales by Immunic, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $130.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:23 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | – | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating expenses | $103.2M | $98.1M | $99.2M | $119.5M | $91.7M |
| Research and development | $82.0M | $80.0M | $83.2M | $71.3M | $61.1M |
| Selling, general and administrative | $21.2M | $18.0M | $16.0M | $15.3M | $13.3M |
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M |
| Income tax | $0 | – | – | – | – |
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M | -$92.9M |
| EPS, basic | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 |
| EPS, diluted | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 |
| Weighted shares, basic | 155.7M | 100.2M | 44.3M | 31.8M | 23.7M |
| Weighted shares, diluted | 155.7M | 100.2M | 44.3M | 31.8M | 23.7M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | – | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Cash and equivalents | $15.5M | $35.7M | $46.7M | $106.7M | $86.9M |
| Total current assets | $22.9M | $39.3M | $52.5M | $125.9M | $105.0M |
| Property, plant and equipment | $608.0K | $545.0K | $466.0K | $294.0K | $152.0K |
| Goodwill | – | – | – | $0 | $33.0M |
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M |
| Accounts payable | $10.1M | $7.85M | $5.10M | $4.28M | $3.75M |
| Total current liabilities | $30.6M | $22.2M | $24.7M | $13.1M | $11.4M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M |
| Shareholders' equity | -$6.67M | $18.4M | $28.9M | $113.7M | $127.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | – | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating cash flow | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M |
| Capital expenditures | $161.0K | $264.0K | $334.0K | $112.0K | $67.0K |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M |
| Depreciation and amortization | $168.0K | $134.0K | $111.0K | $77.0K | $85.0K |
| Stock-based compensation | $8.86M | $8.53M | $7.10M | $7.93M | $5.95M |
| Investing cash flow | -$161.0K | -$264.0K | $9.46M | -$9.74M | -$67.0K |
| Financing cash flow | $65.6M | $74.5M | $1.03M | $95.8M | $42.8M |
| Net change in cash | -$20.2M | -$11.0M | -$60.1M | $19.9M | -$40.6M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 15.9M | −86.8% | SEC |
| Jul 31, 2026 | 13.6M | −86.2% | SEC |
| Apr 30, 2026 | 13.6M | −85.8% | SEC |
| Apr 16, 2026 | 136.2M | +42.2% | SEC |
| Feb 20, 2026 | 130.5M | +44.7% | SEC |
| Nov 7, 2025 | 120.3M | +33.5% | SEC |
| Jul 31, 2025 | 98.7M | +9.5% | SEC |
| May 14, 2025 | 95.8M | +6.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-10 in Q2 2026.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.